Results

1–9 of 9 results for exudative AMD

RO-104, a Novel Trispecific Antibody, Significantly Reduces Lesion Area and Vascular Leakage in a Laser-Induced Nonhuman Primate CNV Model
Harit K. Bhatt, MD, MBA, FASRS, FACS
Annual Meeting Talks
2025
Complement Inhibition Treatment for Geographic Atrophy in Eyes With Exudative AMD
Josh Wallsh
Annual Meeting Talks
2025
Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Using New Sialic Acid-Coated Nanoparticles
Carl D. Regillo, MD
Annual Meeting Talks
2023
Modulation of Macrophages and Complement Dysfunction in Nonexudative AMD Utilizing Novel Sialic Acid-Coated Nanoparticles
Robert L. Avery, MD
Updates from the Field
2024
APEX: A Phase II Randomized Clinical Trial Evaluating the Safety andPreliminary Efficacy of X-82 Administered Orally in the Treatment of Exudative AMD
Michael N. Cohen, MD
Updates from the Field
2020
Massive SRH in Patient on Coumadin Being Treated for Exudative AMD
John S. King, MD
Retina Image Bank: Images of the Week
2019
Safety and Efficacy of Risuteganib in Intermediate Nonexudative AMD: First Time Results From a Phase 2 Study
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2019
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes With Nonexudative AMD Trial (PREVENT) A Prospective Controlled Clinical Trial
Maziar Lalezary, MD, FASRS
Annual Meeting Talks
2018
Prophylactic Ranibizumab for Exudative AMD in Vulnerable Eyes with Nonexudative AMD Trial (PREVENT): A Prospective Controlled
Maziar Lalezary, MD, FASRS
Updates from the Field
2018